ODAC Recommends Accelerated Approval
Perjeta Poised to Blaze a New Trail in Neoadjuvant Breast Cancer Therapy
By Catherine Shaffer
Friday, September 13, 2013
The FDA’s Oncologic Drugs Advisory Committee voted 13 - 1 Thursday to support approval of Genentech Inc.’s supplemental biologics license application for Perjeta (pertuzumab) in neoadjuvant (preoperative) treatment of breast cancer. The application is the first for a neoadjuvant indication.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.